THE European Medicines Agency (EMA) has issued a risk alert around cancer medicine Lynparza (olaparib) which is marketed in Australia by AstraZeneca.
The dosing is different for caps and tabs meaning they can't be swapped without dosage adjustment.
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Apr 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Apr 19
